Market Tracker

12/09 5:16pm ET

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

6.01
Delayed Data
As of Dec 09
 +0.05 / +0.84%
Today’s Change
2.80
Today|||52-Week Range
7.80
+19.01%
Year-to-Date
This Is Why Keryx Biopharmaceuticals Surged 28% in November
Dec 06 / MotleyFool.com - Paid Partner Content
3 Biotech Investing Tips That Could Earn You Thousands
Nov 28 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close5.96
Today’s open6.00
Day’s range5.87 - 6.20
Volume1,192,749
Average volume (3 months)1,572,225
Market cap$631.5M
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)+3.25%
Earnings growth (this year)-17.99%
Earnings growth (next 5 years)+30.00%
Revenue growth (last year)+26.37%
P/E ratioNM
Price/Sales38.35
Price/Book7.21

Competitors

 Today’s
change
Today’s
% change
ENTAEnanta Pharmaceutica...+0.19+0.58%
PGNXProgenics Pharmaceut...+0.28+3.16%
FLXNFlexion Therapeutics...+0.06+0.31%
GBTGlobal Blood Therape...0.000.00%
Data as of 4:00pm ET, 12/09/2016

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.21
Annual revenue (last year)$13.7M
Annual profit (last year)-$123.1M
Net profit margin-900.18%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Gregory P. Madison
Chief Financial Officer
Scott A. Holmes
Corporate headquarters
Boston, Massachusetts

Forecasts